Technical brief |

MPP licence agreement with AbbVie for glecaprevir/pibrentasvir

Photograph by Dean Irvine

In November 2018, the Medicines Patent Pool (MPP) announced a licence agreement with the pharmaceutical company AbbVie for glecaprevir/pibrentasvir (G/P), a fixed-dose combination direct-acting antiviral (DAA) therapy used for the treatment of hepatitis C virus (HCV) infection.

This briefing document examines the key features of the voluntary licence agreement and the extent to which the terms and conditions may contribute to access to generic versions of G/P, together with other DAA treatment options, in developing countries. While the licence has some positive characteristics, there are multiple shortcomings that can be improved, concerning both the practical implications of the licence terms and the licence’s influence on access to affordable generic DAAs for patients in developing countries.